Pharma Journalist 9017 posts 0 comments

Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, announced it has acquired the rights to two preclinical-stage…
Read More...

Gilead Sciences, Inc. and Jounce Therapeutics, Inc. amended their existing license agreement for GS-1811, enabling Gilead to buy out remaining contingent payments potentially due under…
Read More...

AstraZeneca’s immunotherapies Imfinzi (durvalumab) and Imjudo (tremelimumab) have been approved in Japan for the treatment of three cancer types: advanced liver, biliary tract and lung.…
Read More...

Following the formation of Mayflower Bioventures, a cell and gene therapy accelerator stood up from Hibiscus BioVentures and Mayo Clinic, comes the launch of their first start-up,…
Read More...

Global biotechnology leader CSL announced that the U.S. Food and Drug Administration (FDA) approved HEMGENIX (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy…
Read More...

Berkeley Lights, a life sciences tools company, and IsoPlexis, a company empowering labs to leverage the cells and proteome changing the course of human health, announced a definitive…
Read More...

Skye Bioscience, Inc., a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announced that the U.S. Food and Drug Administration…
Read More...

Kite, a Gilead Company and Tmunity Therapeutics (Tmunity) announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech…
Read More...

Sanofi and Innate Pharma SA announced an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKETTM …
Read More...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced…
Read More...